NN 9161Alternative Names: '2-0453; NN9161; NNC0070-0002-0453
Latest Information Update: 25 Mar 2017
At a glance
- Originator Novo Nordisk
- Class Obesity therapies; Proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 30 Nov 2011 Discontinued - Phase-I/II for Obesity in USA (SC)
- 13 Jul 2010 Novo Nordisk completes enrolment in its phase I/II trial (NCT01044108) for Obesity in USA
- 06 Jan 2010 Phase-I/II clinical trials in Obesity in USA (SC)